Safety and Effectiveness of Combined PRP and Botulinum Toxin Type A Injections for Treating Androgenetic Alopecia in Adults Aged 18 to 60

What this Trial Is About

Researchers are studying the safety and effectiveness of combining platelet-rich plasma PRP and Botulinum Toxin Type A BTX-A injections to treat Androgenetic Alopecia AGA, a common form of hair loss. This Phase 2 clinical trial involves adult patients aged 18 to 60 with specific stages of AGA. The study is randomized, controlled, and conducted at multiple centers, enrolling a total of 76 patients. Participants are divided into two groups. One group receives PRP injections combined with BTX-A during the first session, followed by PRP-only injections in the subsequent two monthly sessions. The other group receives only PRP injections every month for three months. Injections are given intradermally on defined scalp areas, with specific dosage and spacing guidelines. Both groups undergo safety evaluations 14 days after the first treatment, along with scalp care advice. Throughout the study, participants will have assessments at 1, 2, 3, and 6 months after treatment to monitor safety and measure hair density changes. These evaluations help researchers understand treatment effects over time. The total participation duration includes the treatment period and follow-up assessments, ensuring thorough monitoring of outcomes and participant well-being.

PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study